Certolizumab Pegol Shows Promise in Reducing Adverse Pregnancy Outcomes in High-Risk APS Patients: Insights from the IMPACT Trial
The IMPACT trial demonstrates that adding certolizumab pegol to standard therapy reduces placenta-mediated adverse pregnancy outcomes in women with antiphospholipid syndrome and lupus anticoagulant, with favorable safety and neonatal outcomes.